An update from Avalo Therapeutics ( (AVTX) ) is now available.
On March 25, 2025, Avalo Therapeutics appointed Michael Heffernan as Chairman of the Board, succeeding Dr. Garry Neil, who will remain as CEO and a Board member. This strategic move aims to leverage Heffernan’s extensive experience in biopharmaceuticals to advance Avalo’s pipeline, particularly the Phase 2 LOTUS trial for hidradenitis suppurativa, and aligns with the company’s growth and strategic direction.
More about Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on treating immune dysregulation. Its lead asset, AVTX-009, is an anti-IL-1β monoclonal antibody targeting inflammatory diseases.
YTD Price Performance: 1.30%
Average Trading Volume: 78,576
Technical Sentiment Signal: Buy
Current Market Cap: $91.14M
For detailed information about AVTX stock, go to TipRanks’ Stock Analysis page.